litlas
Log inCreate account

Tal Zaks

Active 1998–2024

31
Papers
20,568
Citations
27
h-index
30
i10-index

Citations

Citations per year for Tal Zaks1969: 1 citations1974: 1 citations1999: 10 citations2000: 25 citations2001: 17 citations2002: 27 citations2003: 14 citations2004: 25 citations2005: 35 citations2006: 35 citations2007: 32 citations2008: 40 citations2009: 47 citations2010: 49 citations2011: 53 citations2012: 47 citations2013: 39 citations2014: 40 citations2015: 34 citations2016: 26 citations2017: 30 citations2018: 41 citations2019: 110 citations2020: 189 citations2021: 2,218 citations2022: 1,879 citations2023: 1,146 citations2024: 1,586 citations2025: 1,079 citations2026: 36 citations1970–1973: no citations, so these years are not shown1975–1998: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,479 citing papers, 27.6% of this breakdownChina: 1,328 citing papers, 10.5% of this breakdownUnited Kingdom: 733 citing papers, 5.8% of this breakdownGermany: 549 citing papers, 4.3% of this breakdownItaly: 501 citing papers, 4% of this breakdownCanada: 463 citing papers, 3.7% of this breakdownFrance: 327 citing papers, 2.6% of this breakdownAustralia: 324 citing papers, 2.6% of this breakdownJapan: 310 citing papers, 2.4% of this breakdownSpain: 291 citing papers, 2.3% of this breakdownSouth Korea: 289 citing papers, 2.3% of this breakdownIndia: 285 citing papers, 2.2% of this breakdown
0%27.6%Other 29.7%

Institutions

Fields

  • Medicine54.7%
  • Biochemistry, Genetics and Molecular Biology28.9%
  • Immunology and Microbiology7.9%
  • Social Sciences2%
  • Materials Science1.4%
  • Engineering1.1%
  • Other4%

Topics

  • SARS-CoV-2 and COVID-19 Research14.6%
  • RNA Interference and Gene Delivery8.2%
  • COVID-19 Clinical Research Studies5.4%
  • Immunotherapy and Immune Responses5.2%
  • Vaccine Coverage and Hesitancy3.6%
  • Advanced biosensing and bioanalysis techniques2.9%
  • Other60.1%

Coauthors

All papers

Open in search
  1. Lipid nanoparticles for mRNA delivery

    Authors: Xucheng Hou, Tal Zaks, Róbert Langer, Yizhou Dong - Nature Reviews Materials 2021 cited by 3,651

  2. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

    Authors: Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Karen Kotloff, Sharon Frey, Rick Novak, David Diemert, Stephen A. Spector, Nadine Rouphael, C. Buddy Creech, John McGettigan, Shishir Khetan, Nathan Segall, Joel Solis, Adam Brosz, Carlos Fierro, Howard Schwartz, Kathleen Neuzil, Lawrence Corey, Peter Gilbert, Holly Janes, Dean Follmann, Mary Marovich, John Mascola, Laura Polakowski, Julie Ledgerwood, Barney S. Graham, Hamilton Bennett, Rolando Pajon, Conor Knightly, Brett Leav, Weiping Deng, Honghong Zhou, Shu Han, Melanie Ivarsson, Jacqueline Miller, Tal Zaks - New England Journal of Medicine 2020 cited by 10,720

  3. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

    Authors: Jeffrey S. Weber, Matteo S. Carlino, Adnan Khattak, Tarek Meniawy, George Ansstas, Matthew H. Taylor, Kevin B. Kim, Meredith McKean, Georgina V. Long, Ryan J. Sullivan, Mark B. Faries, Thuy Tran, C. Lance Cowey, Andrew L. Pecora, Montaser Shaheen, Jennifer Segar, Theresa Medina, Victoria Atkinson, Geoffrey T. Gibney, Jason J. Luke, Sajeve Thomas, Elizabeth I. Buchbinder, Jane A Healy, Mo Huang, Manju Morrissey, Igor Feldman, Vasudha Sehgal, Céline Robert-Tissot, Peijie Hou, Lili Zhu, Michelle Brown, Praveen Aanur, Robert Meehan, Tal Zaks - The Lancet 2024 cited by 739

  4. mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer

    Authors: Gal Cafri, Jared J. Gartner, Tal Zaks, Kristen Hopson, Noam Levin, Biman C. Paria, Maria R. Parkhurst, Rami Yossef, Frank J. Lowery, Mohammad Jafferji, Todd D. Prickett, Stephanie L. Goff, Christine T. McGowan, Samantha J. Seitter, Mackenzie L. Shindorf, Anup Y. Parikh, Praveen D. Chatani, Paul F. Robbins, Steven A. Rosenberg - Journal of Clinical Investigation 2020 cited by 414

  5. Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses

    Authors: Kapil Bahl, Joe J. Senn, Olga Yuzhakov, Alex Bulychev, Luis A. Brito, Kimberly J. Hassett, Michael E. Laska, Mike Smith, Örn Almarsson, James Thompson, Amilcar Ribeiro, Mike Watson, Tal Zaks, Giuseppe Ciaramella - Molecular Therapy 2017 cited by 654

  6. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials

    Authors: Robert Feldman, Rainard Fuhr, Igor Smolenov, Amilcar Ribeiro, Lori Panther, Michael Watson, Joseph J. Senn, Mike Smith, Örn Almarsson, Hari Pujar, Michael E. Laska, James D. Thompson, Tal Zaks, Giuseppe Ciaramella - Vaccine 2019 cited by 463

  7. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus

    Authors: Allison August, Husain Attarwala, Sunny Himansu, Shiva Kalidindi, Sophia Lu, Rolando Pajón, Shu Han, Jean‐Michel Lecerf, Joanne E. Tomassini, Marjie Hard, Leon M. Ptaszek, James E. Crowe, Tal Zaks - Nature Medicine 2021 cited by 186

  8. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults

    Authors: Antonios O. Aliprantis, Christine A. Shaw, Paul Griffin, Nicholas Farinola, Radha Railkar, Xin Cao, Wen Liu, Jeffrey R. Sachs, Christine J. Swenson, Heather Lee, Kara S. Cox, Daniel S. Spellman, Colleen J. Winstead, Igor Smolenov, Eseng Lai, Tal Zaks, Amy S. Espeseth, Lori Panther - Human Vaccines & Immunotherapeutics 2020 cited by 151

  9. mRNA-encoded, constitutively active STINGV155M is a potent genetic adjuvant of antigen-specific CD8+ T cell response

    Authors: Sze-Wah Tse, Kristine McKinney, William H. Walker, Mychael Nguyen, Jared Iacovelli, Clayton Small, Kristen Hopson, Tal Zaks, Eric Yi‐Hsiu Huang - Molecular Therapy 2021 cited by 102

  10. Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults

    Authors: Allison August, Christine A. Shaw, Heather Lee, Conor Knightly, Shiva Kalidindia, Laurence Chu, Brandon Essink, William Seger, Tal Zaks, Igor Smolenov, Lori Panther - Open Forum Infectious Diseases 2022 cited by 83

  11. A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.

    Authors: Howard A. Burris, Manish R. Patel, Daniel C. Cho, Jeffrey Clarke, Martin Gutierrez, Tal Zaks, Joshua P. Frederick, Kristen Hopson, Kinjal Mody, Alverina Binanti-Berube, Céline Robert-Tissot, Bree Goldstein, Ben Breton, Jing Sun, Shan Zhong, Scott K. Pruitt, Karen Keating, Robert Meehan, Justin F. Gainor - Journal of Clinical Oncology 2019 cited by 144

  12. Abstract CT001: A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201/Keynote-942 trial

    Authors: Adnan Khattak, Matteo S. Carlino, Tarek Meniawy, George Ansstas, Theresa Medina, Matthew H. Taylor, Kevin B. Kim, Meredith McKean, Georgina V. Long, Ryan J. Sullivan, Mark B. Faries, Thuy B. Tran, C. Lance Cowey, Andrew L. Pecora, Jennifer Segar, Victoria Atkinson, Geoffrey T. Gibney, Jason J. Luke, Sajeve Thomas, Elizabeth I. Buchbinder, Peijie Hou, Lili Zhu, Tal Zaks, Michelle Brown, Praveen Aanur, Robert Meehan, Jeffrey S. Weber - Cancer Research 2023 cited by 49

  13. Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects

    Authors: David A. Tuveson, Alice T. Shaw, Nicholas A. Willis, Daniel P. Silver, Erica L. Jackson, Sandy Chang, Kim L. Mercer, Rebecca Grochow, Hanno Hock, Denise Crowley, Sunil R. Hingorani, Tal Zaks, Catrina E. King, Michael A. Jacobetz, Lifu Wang, Roderick T. Bronson, Stuart H. Orkin, Ronald A. DePinho, Tyler Jacks - Cancer Cell 2004 cited by 816

  14. Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases

    Authors: Fawn Qian, Stefan Engst, Toshihiro Yamaguchi, Peiwen Yu, Kwang‐Ai Won, Lillian Mock, Tracy Lou, Jenny Tan, Connie Li, Danny Tam, Julie C. Lougheed, F. Michael Yakes, Frauke Bentzien, Wei Xu, Tal Zaks, Richard Wooster, Joel Greshock, Alison Joly - Cancer Research 2009 cited by 338

  15. A phase 1, open-label, multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in subjects with resected solid tumors and in combination with pembrolizumab in subjects with unresectable solid tumors (Keynote-603).

    Authors: Howard A. Burris, Manish R. Patel, Daniel C. Cho, Jeffrey Clarke, Martin Gutierrez, Tal Zaks, Joshua P. Frederick, Kristen Hopson, Kinjal Mody, Alverina Binanti-Berube, Céline Robert-Tissot, Kristen Cowens, Ben Breton, Shan Zhong, Honghong Zhou, Pamela Cohen, Karen Keating, Robert Meehan, Justin F. Gainor - Journal of Global Oncology 2019 cited by 25

  16. Cancer therapy using a self-replicating RNA vaccine

    Authors: Ying Han, Tal Zaks, Rong‐Fu Wang, Kari R. Irvine, Udai S. Kammula, Francesco M. Marincola, Wolfgang W. Leitner, Nicholas P. Restifo - Nature Medicine 1999 cited by 324

  17. Author Correction: Lipid nanoparticles for mRNA delivery

    Authors: Xucheng Hou, Tal Zaks, Róbert Langer, Yizhou Dong - Nature Reviews Materials 2021 cited by 33

  18. Immunogenicity and tolerability of personalized mRNA vaccine mRNA-4650 encoding defined neoantigens expressed by the autologous cancer.

    Authors: Gal Cafri, Jared J. Gartner, Kristen Hopson, Robert Meehan, Tal Zaks, Paul F. Robbins, Steven A. Rosenberg - Journal of Clinical Oncology 2019 cited by 26

  19. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

    Authors: Amir Massarweh, Noa Eliakim‐Raz, Amos Stemmer, Adva Levy‐Barda, Shlomit Yust‐Katz, Alona Zer, Alexandra Benouaich‐Amiel, Haim Ben‐Zvi, Neta Moskovits, Baruch Brenner, Jihad Bishara, Dafna Yahav, Boaz Tadmor, Tal Zaks, Salomon M. Stemmer - JAMA Oncology 2021 cited by 291

  20. Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer

    Authors: Helen J. Ross, George R. Blumenschein, Joseph Aisner, Nevena Damjanov, Afshin Dowlati, Jennifer Garst, James R. Rigas, Michael Smylie, Habib Hassani, Kimberly E. Allen, Lance Leopold, Tal Zaks, Frances A. Shepherd - Clinical Cancer Research 2010 cited by 119

  21. INDUCTION OF PROINFLAMMATORY AND CHEMOKINE GENES BY LIPOPOLYSACCHARIDE AND PACLITAXEL (Taxol™) IN MURINE AND HUMAN BREAST CANCER CELL LINES

    Authors: Meirav Zaks‐Zilberman, Tal Zaks, Stefanie N. Vogel - Cytokine 2001 cited by 101

  22. Safety and immunogenicity of a mRNA-based chikungunya vaccine in a phase 1 dose-ranging trial

    Authors: Christine A. Shaw, Lori Panther, Allison August, Tal Zaks, Igor Smolenov, Stephan Bart, M. Watson - International Journal of Infectious Diseases 2019 cited by 32

  23. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study

    Authors: Bella Kaufman, Maureen Trudeau, Ahmad Awada, Kimberly Blackwell, Thomas Bachelot, Vanessa Salazar, Michelle DeSilvio, Ronald Westlund, Tal Zaks, Neil L. Spector, Stephen Johnston - The Lancet Oncology 2009 cited by 118

  24. Cancer Cell Lines as Genetic Models of Their Parent Histology: Analyses Based on Array Comparative Genomic Hybridization

    Authors: Joel Greshock, Katherine L. Nathanson, Anne‐Marie Martin, Lin Zhang, George Coukos, Barbara Weber, Tal Zaks - Cancer Research 2007 cited by 82